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Abstract Technological advances in DNA sequencing have
made gene testing fast and more affordable. Evidence of ef-
fectiveness and cost-effectiveness of genetic service models is
essential for the successful translation of sequencing improve-
ments for patient benefit, but remain sparse in the genetics
literature. In particular, there is a lack of detailed cost data
related to genetic services. A detailed micro-costing of 28
possible pathways relating to breast and/or ovarian cancer
and BRCA testing was carried out by defining service activ-
ities and establishing associated costs. These data were com-
bined with patient-level data from a Royal Marsden Cancer
Genetics Service audit over a 6-month period during which
BRCA testing was offered to individuals at ≥10 % risk of
having a mutation, in line with current NICE guidance. The
average cost across all patient pathways was £2227.39 (range
£376.51 to £13,553.10). The average cost per pathway for an
affected person was £1897.75 compared to £2410.53 for an
unaffected person. Of the women seen in the Cancer Genetics
Service during the audit, 38 % were affected with breast and/
or ovarian cancer, and 62 % were unaffected but concerned
about their family history. The most efficient service strategy
is to identify unaffected relatives from an affected individual
with an identified BRCA mutation. Implementation of this
strategy would require more comprehensive testing of all eli-
gible cancer patients, which could be achieved by integrating
BRCA testing into oncology services. Such integration would
be alsomore time-efficient and deliver greater equity of access
to BRCA testing than the standard service model.
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Introduction
Health care policy initiatives in recent years in the United
Kingdom(UK)andelsewherehaverecommendedthathealthcare
services integrate advances in genomic technologies and knowl-
edge into clinical practice for the benefit of patients (BOur
Inheritance, Our Future. Realising the potential of genetics in
the NHS.^ 2003; BGenomic Medicine^ 2009; Brand and Lal
2012; BRealising the potential of stratified medicine^ 2013).
The technological advances are increasingly enabling gene test-
ing to be offered via multigene panel, exome or whole genome
testing which potentially allows greater throughput of samples
and significant economies of scale (Shendure et al. 2004).
However, the decision-making process regarding the affordabil-
ity of the expansion and integration of genomic technologies into
health services is impeded by limited clarity of where costs lie in
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the current standard genetic servicemodel(s) andwhere genomic
testing could best fit into thesemodels.
Clinical cancer genetic units offer services to individuals
and families with the goal of assisting treatment decisions in
patients with a cancer diagnosis and facilitating early cancer
detection and cancer prevention for any future cancers for
them and their relatives. Mutations of over 100 genes are
known to cause an increased risk of cancer, and these underlie
approximately 3 % of cancer overall (Rahman 2014; Vencken
et al. 2013). There is strong evidence that identification of
cancer predisposition gene mutations has an impact on diag-
nosis and management of cancer patients and their families
(Rahman 2014; Vencken et al. 2013; Byrski et al. 2012;
Turner and Tutt 2012; Fong et al. 2009).
A large proportion of the work of any cancer genetic ser-
vice is the management of familial breast and ovarian cancer.
Germline mutations in BRCA1 and BRCA2 (collectively
termed ‘BRCA’) underlie a proportion of both these cancers,
and the most recent guidelines for familial breast cancer in the
UK published in 2013 recommend testing individuals at
≥10 % chance of having a mutation (NICE 2013).
Typically in theUK,andmanyothercountries,patients requir-
ing assessment for cancer gene testing are referred to a cancer
genetic service, where application of risk thresholds, such as the
10% threshold forBRCA testing, recommended by theNational
InstituteforHealthandCareExcellence(NICE)isusedtomanage
resource allocation (NICE 2013). However, it has been demon-
strated that not all those eligible for testing are being referred to
cancergenetic services.Forexample,∼15%ofhigh-gradeserous
ovarian cancer is due to germline BRCAmutations and thus are
eligible for testing at a 10 % risk threshold (Alsop et al. 2012;
Zhanget al. 2011).However, referral of ovariancancer patients to
genetic services is very low, around 7–20 % (Alsop et al. 2012;
Zhang et al. 2011; Fong et al. 2009). In part, this is because only
about half of mutation-positive ovarian cancer patients report a
significant familyhistoryofcancer (Alsopetal.2012;Zhangetal.
2011). Clearly, important opportunities for improved manage-
ment of ovarian cancer patients and cancer prevention in their
relatives are being missed through the existing processes.
Moreover, the cancer genetic service delivery model has limited
staff numbers and an infrastructure that is not easily adapted to
accommodate unmet need, or to address the increasing demand
for cancer gene testing (Fong et al. 2009).
Evidence of effectiveness and cost-effectiveness of service
models, including the use of genomic technologies, is essen-
tial for policy-making frameworks but remains sparse in the
genetics and genomics literature (Sullivan et al. 2012). In par-
ticular, there is lack of cost data, including readily available
published reference costs, for genetic services. Micro-costing
is a detailed costing approach and requires identification, mea-
surement and valuation of all underlying activities of a service
(Gray et al. 2011). In this paper, we present a full micro-cost-
ing, from the healthcare provider perspective, of a cancer
genetic service for breast and ovarian cancer within the UK
National Healthcare Service (NHS) from referral to
management.
Our study was undertaken as part of the Mainstreaming
Cancer Genetics (MCG) programme (www.mcgprogramme.
com), a translational initiative that is developing the assays,
informatics, clinical infrastructure, education and evaluation
to allow implementation of cancer gene testing into routine
clinical care of cancer patients and their relatives.
Methods
To perform the micro-costing, we first mapped out all the
possible pathways relating to breast and/or ovarian cancer
and BRCA testing that a patient may follow when referred
to the Royal Marsden Cancer Genetics Service prior to the
implementation of mainstream testing in June 2013. We be-
lieve these to be generally representative of most cancer ge-
netic services in the UK in 2014. Once completed, the service
activities and resources involved in each step of every path-
way were defined and the costs for each activity established so
that the overall cost of each patient pathway could be calcu-
lated based on 2013 costs.
Pathway costings
The patient pathways were defined from referral to surveillance
management using service protocols and in discussion with the
Cancer Genetics Unit at the Royal Marsden NHS Foundation
Trust in London (Figs. 1 and 2). The management strategy for
each patient was as described in the Royal Marsden Cancer
Genetics management protocols in use during the audit period
(Supplementary Figure 1). These are based on offering testing
to those with ≥10% risk threshold of having a BRCAmutation,
in linewith the current NICE guidance (NICE 2013). If a BRCA
mutation is not identified, surveillance recommendations are
made according to the individual’s family history. Population
surveillance recommendation was costed for mammography 3
yearly from 50 to 70 years of age; moderate risk surveillance is
annualmammography from40 to 50 years of age and then enter-
ing the population surveillance; higher risk surveillance is annual
mammography40to50years18monthlymammogramsfrom50
to 60 years and then entering the population surveillance pro-
grammeasperRMHprotocols (SupplementaryFigure2) (2011).
In order to maintain a manageable number of patient path-
ways, in families with no BRCA mutation, it was assumed that
relatives were in the same risk group as the proband. In families
where an individual with a BRCA mutation is identified, rela-
tives either carry the mutation (or chose not to be tested) with
subsequent surveillance management as mutation carriers, or
they do not carry the familial mutation and are managed with
population-level surveillance through the NHS. For individuals
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where a BRCA mutation is identified, carrier surveillance com-
prises annual mammography 40 to 70 years and annual MRI 30
to 50 years. In addition, mutation carriers are eligible for risk-
reducing surgery, bilateral mastectomy and/or bilateral salpingo-
oophorectomy. The uptake of these interventions in unaffected
carriers was determined using expert opinion from the clinical
unit alongside literature estimates, 30 % for bilateral mastecto-
my and 60 % for bilateral salpingo-oophorectomy (Metcalfe
et al. 2008; Meijers-Heijboer et al. 2003; Evans et al. 2009).
For affected carriers, the 5-year survival rate at age 40 years
(0.7 for breast cancer and 0.69 for ovarian cancer www.ons.
gov.uk) was incorporated. It was assumed that 5 % of ovarian
cancer patients with a BRCA mutation that survive to 5 years
would undergo bilateral mastectomy. These rates were based on
discussions with the Royal Marsden Cancer Genetics Unit, as
no published data were available.
In order to identify resource use in each pathway clinical,
administrative and laboratory staff were asked to estimate the
length of time each defined activity took them in minutes, the
general quantity of consumables and where each activity took
place in the pathway. The full BRCA test includes compre-
hensive analysis of the full coding sequence and intron-exon
boundaries for small intragenic mutations and larger exonic
deletion/duplications. A predictive test describes a targeted
analysis for a specific mutation already known to predispose
to cancer in the family. For this paper, we used the
TGLclinical Sanger sequencing+MLPA sequencing cost for
full gene testing, which was charged to the Royal Marsden
NHS Foundation Trust in 2013 exclusive of VAT costs as per
NICE guidance. It should be noted that there is variability in
BRCA gene test costs across the NHS, and the TGLclinical
test cost was at the lower end of the range. The NICE guidance
used a comparable test cost of £700 which is reflected in the
sensitivity analysis (NICE 2013). Additionally, the testing is
now performed with NGS technology using the TruSight
Cancer Panel (see www.TGLclinical.com for further details).
The cost of post genetic testing management, which includes
mammography, MRI, mastec tomy and salpingo-
oopherectomy, was taken from 2013 NHS reference costs
(NHS reference costs 2012) which are published average
Fig. 1 Individual affected with breast or ovarian cancer-patient pathways
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costs derived from hospital trust submissions and the literature
(Taylor-Phillips et al. 2012; NICE 2013) (Table 1).
Staff salary unit costs for administrators, laboratory and
clinical staff were obtained from either the NHS agenda for
change or the Personal Social Services Research Unit
(PSSRU) reference costs for 2013 (Unit costs of health and
social care 2012). The mid-point of each grade was used and
National Insurance, superannuation and overhead costs added
if not already included. In addition, the cost of genetic
counsellor time accounts for supervision at a ratio of 1 h
consultant supervision to 12.5 h counsellor time (Torrance
et al. 2006). All staff time was calculated with a London
weighting of 1.19 as outlined in the PSSRU (reference costs)
(Table 1) (Unit costs of health and social care 2012). The
costs of clinical appointments were taken from the 2012–
2013 NHS reference costs (oncology) and PSSRU costs (gen-
eral practice) (Unit costs of health and social care 2012;
NHS reference costs 2012).
The main (base case) analysis assumes that those affected
by cancer were referred through their oncologist, and those
unaffected by cancer were referred by their general practition-
er. This analysis is restricted to women not within populations
in whom BRCA founder mutation testing is available, such as
the Ashkenazi Jewish population. Furthermore, the base case
analysis assumes that all women are seen in the cancer genetic
service at the age of 30 years. This age was chosen as it
accommodates the years of highest relative risk of both breast
and ovarian cancer in BRCA mutation carriers (Antoniou
et al. 2003). All costs are presented in 2013 pounds Sterling
and assumed to be incurred at the point of service delivery
with the exception of surveillance which continues until the
age of 70 years and hormone replacement therapy which con-
tinues until the age of 50 years. A discount rate of 3.5 % was
applied to the costs associated with surveillance and hormone
replacement therapy (Gray et al. 2011). This discounting rate
adjusts the costs to reflect both time preference and the fact
that items depreciate over time. Risk-reducing surgery is as-
sumed to take place in the year of diagnosis and therefore not
subject to discounting.
Audit data
An audit of all clinical activity relating to breast and/or
ovarian cancer patients or unaffected patients with a
family history of breast and/or ovarian cancer was un-
dertaken at the Royal Marsden Cancer Genetics Service
between September 2009 and February 2010. These data
were used to determine the number of patients, at first
Fig. 2 Individual unaffected-patient pathways
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appointment, that followed each patient pathway within
the audit period. Women, with breast and/or ovarian
cancer, whose consultation was in relation to BRCA
testing, were included; excluding those tested for foun-
der mutations and other cancer predisposition genes and
male patients. This audit excludes those that were inap-
propriately referred or failed to attend appointments.
Sensitivity analysis
In order to examine how sensitive the costing results were
likely to be to any assumptions that we made, sensitivity anal-
ysis was performed where some elements of resource use and
costs were varied. The costs varied in the sensitivity analysis
included member of clinical team involved in the patient path-




A total of 28 individual patient pathways were identified for
the delivery of the breast and ovarian cancer genetic services,
which are split into individuals affected and unaffected by
cancer. A full description of all 28 pathways and their associ-
ated costs are included in the supplementary information
(Supplementary Tables 1 and 2). Pathway 6 is shown in
Table 2, as an exemplar, was chosen as it is the most frequent
affected pathway. This pathway is for an affected individual
eligible for BRCA testing, who has a negative BRCA test.
The supplementary tables and Table 3 give a detailed
breakdown of these pathways, but in summary, path-
ways 1 to 10 represent individuals referred to the cancer
genetic service, who were affected with breast and/or
ovarian cancer (affected patient pathways). The main
differences between these 10 pathways are related to
whether individuals are considered to be eligible for
BRCA testing, whether they decide to undergo testing,
and their subsequent management based on the test re-
sult and their family history.
Pathways 11 to 28 represent individuals referred to cancer
genetic services, who are not affected with cancer (unaffected
patient pathways). The main differences between these path-
ways are related to whether a relative of the individual has
previously undergone BRCA mutation testing, and if not,
whether the individual or a relative is eligible for BRCA test-
ing, and their subsequent management based on the test result
and their family history.
Table 1 Unit costs for clinical
activity and patient management
costs (2013)
Cost items Cost (£) Source of data
Genetic service activity
Referral received and processed 5.07 Primary data collection
Referral triaged 1.17 Primary data collection
Request documents 8.82 Primary data collection
Clinical review of case 21.85 Primary data collection
Appointment arranged 3.49 Primary data collection
Clinic preparation 2.74 Primary data collection
Clinic appointment 104.80 Primary data collection
Post appointment letter 11.18 Primary data collection
Post appointment administration 5.17 Primary data collection
Staff salaries (London)
Band 3, administrative assistant 17.19 per hour NHS Agenda for change
Band 5, medical secretary 23.48 per hour NHS Agenda for change
Band 6, administrative lead 28.74 per hour NHS Agenda for change
Band 8, genetic counsellor 55.54 per hour NHS Agenda for change
Registrar 61.46 per hour PSSRU
Consultant 139.73 per hour PSSRU
Patient management
Mammography 45.50 (Taylor-Phillips et al. 2012)
MRI 145.88 (NHS reference costs 2012)
Mastectomy 6784.00 (NHS reference costs 2012; NICE 2013)
Salpingo-oophorectomy 3355.43 (NICE 2013; NHS reference costs 2012)
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Pathway costs
Table 3 presents the total cost of each individual path-
way. The most expensive pathway (£13,553.10) is that
in which an unaffected individual presents, a relative of
that individual has a BRCA test which is positive and
the unaffected individual is also mutation positive. This
reflects the management costs incurred by both individ-
uals in the family. There are three pathways with the
lowest cost (£376.51), each of which are pathways for
unaffected individuals either from a family where previ-
ous testing has not identified a BRCA mutation, from a
family where no relative is available for testing or from
a family where no BRCA testing is recommended. In
each pathway, the unaffected individual is subsequently
managed at population risk. This lower cost represents
the absence of genetic testing and the lower manage-
ment costs.
The average cost across all 28 patient pathways in the can-
cer genetic services was £2227.39 per pathway, when weight-
ed by the audit data this average was £1760.95. The average
cost per pathway for a person affected with breast or ovarian
cancer was £1897.75 (weighted average £2083.95) compared
to £2410.53 (weighted average £1561.45) for an unaffected
person. The average cost of a pathway where the presenting
patient is found to carry a BRCAmutation was £8069.50, with
a weighted average using audit data of £6657.08, representing
higher management costs in these patients. The average cost
of a pathway where a full BRCA test was carried out in a
presenting patient or relative was £4462.47 (weighted average
£3212.44) compared to £3118.45 (weighted average
£3299.96) when a predictive BRCA test for a knownmutation
is performed. In the situation of BRCA testing being recom-
mended in a relative of the presenting unaffected patient, the
average cost of the pathway rose to £5376.24 (weighted aver-
age £4445.15).
Audit data
A total of 220 women had first appointments, regarding breast
and/or ovarian and BRCA testing, within the Cancer Genetics
Service at the Royal Marsden NHS Foundation Trust, be-
tween September 2009 and February 2010. Of these, 84
(38 %) women were affected with breast and/or ovarian can-
cer, and 136 (62 %) were unaffected but concerned about their
family history. A total of 72 (33 %) women were eligible for
BRCA testing at the first appointment either as a full mutation
screen (n=42) or as a predictive test (n=30).
Of the 84 women with breast and/or ovarian cancer, seen in
first appointments between September 2009 and February
2010, 42 % (35/84) were eligible for, and underwent, BRCA
testing. In nine patients, a mutation was identified. In the 26
where no mutation was identified 23 were eligible for higher
risk surveillance and three for moderate risk surveillance.
Seven women declined genetic testing, all of whom were el-
igible for higher risk surveillance. In 32 women, no testing
was recommended; four were at population risk, 12 were eli-
gible for moderate risk surveillance and 16 for higher risk
Table 2 Example of patient
pathway units of activity, and
associated costs
Pathway 6
Activity Sub activity Cost (£)
Oncology referral Oncology clinic appointment 168.00






Clinic related activity Clinic appointment 104.80
Post appointment letter 11.18
Post appointment administration 5.17
Blood sample Phlebotomy 3.00
BRCA full gene test 540.00
Follow up appointment administration Appointment arranged 3.49
Clinic preparation 2.74
Follow up clinic related activity Clinic appointment 104.80
Post appointment letter 11.18
Post appointment administration 5.17
Higher risk surveillance Mammography 628.30
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surveillance. There were a further 10 women affected
with breast and/or ovarian cancer, who had not them-
selves been tested, but where a familial BRCA mutation
was known.
A total of 136 unaffected individuals were seen in first
appointments during the audit period. In 30/136 cases, there
was a known familial BRCA mutation, 22 of these underwent
predictive testing; seven were found to carry a mutation. There
were 35 of these 136 unaffected women in whom BRCA
testing in a family member was not recommended; eight were
population risk, 18 eligible for moderate risk surveillance and
nine higher risk surveillance.
BRCA testing in a relativewith cancer was recommended for
19 unaffected individuals. In three of these 19 cases, there was a
known familial mutation in a distant relative and an intervening
relative required testing prior to further management of the pa-
tient. In each of these families, the intervening relativewas found
not to carry a BRCA mutation, and therefore, testing was not
carried out in the unaffected patient. In 16 of these 19 cases, it
was recommended that an affected relative had a full BRCA test;
Table 3 Pathway costs
Number Pathway description Pathway
cost
Affected patient pathways
1 Affected individual, BRCA mutation identified £5606.16
2 Affected individual, known familial BRCA mutation identified £5174.16
3 Affected individual, known familial BRCA mutation not identified £739.88
4 Affected individual, declined BRCA testing, higher risk family history £960.59
5 Affected individual, declined BRCA testing, moderate risk family history £911.08
6a Affected individual, BRCA testing negative, higher risk family history £1630.96
7 Affected individual, BRCA testing negative, moderate risk family history £1581.45
8 Affected individual, not eligible for BRCA testing, population surveillance £501.51
9 Affected individual, not eligible for BRCA testing, moderate risk family history £911.08
10 Affected individual, not eligible for BRCA testing, higher risk family history £960.59
Unaffected patient pathways
11 Unaffected individual, known familial BRCA mutation identified £7944.56
12 Unaffected individual, known familial BRCA mutation, test declined £835.59
13 Unaffected individual, known familial BRCA mutation not identified £614.88
14 Unaffected individual, no testing recommended, higher risk family history £835.59
15 Unaffected individual, no testing recommended, moderate risk family history £786.08
16 Unaffected individual, no testing recommended, population risk £376.51
17 Unaffected individual, affected relative eligible for BRCA testing, mutation identified
in affected relative and in individual
£13,553.10
18 Unaffected individual, affected relative eligible for BRCA testing, mutation identified
in affected relative but not in individual
£6223.42
19 Unaffected individual, affected relative eligible for BRCA testing, no mutation
identified in affected relative, higher risk family history
£2707.29
20 Unaffected individual, affected relative eligible for BRCA testing, no mutation
identified, moderate risk family history
£2608.27
21 Unaffected individual, affected relative eligible for BRCA testing, no mutation
identified in relative, population risk
£1789.13
22 Unaffected individual, family eligible for BRCA testing, no relative available or
relative does not get tested, higher risk family history
£835.59
23 Unaffected individual, family eligible for BRCA testing, no relative available or
relative does not get tested, moderate risk family history
£786.08
24 Unaffected individual, family eligible for BRCA testing, no relative available or
relative does not get tested, population risk
£376.51
25 Unaffected individual, known familial BRCA mutation, relative to be tested first,
relative negative
£1118.76
26 Unaffected individual, family already tested, no mutation identified, moderate risk
family history
£786.08
27 Unaffected individual, family already tested, no mutation identified, higher risk
family history
£835.59
28 Unaffected individual, family already tested, no mutation identified, population risk £376.51
a See Table 2 for details of this pathway
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four of these relatives weremutation positive, allowing the unaf-
fected individual to undergo predictive testing. The period of the
audit precludes inclusion of results of these predictive tests, a
probability of 50 % was used to predict that two of these four
unaffected individuals would be BRCA mutation carriers and
two would not. There were 12 relatives found not to carry a mu-
tation; 11 of these were families eligible for higher risk surveil-
lance, and one was at population risk.
For 12 unaffected individuals, an affected relative had al-
ready been tested and found to be negative for BRCA muta-
tions. Three were eligible for moderate risk surveillance and
nine for higher risk surveillance. For 40 unaffected individ-
uals, their families were potentially eligible for testing, but
either no relative with cancer was available for testing, a rel-
ative was informed about eligibility but did not have testing or
the unaffected individual decided not to proceed with testing.
Thirty-two of these unaffected individuals were eligible for
higher risk surveillance and five for moderate risk surveil-
lance. Three cases were at population risk.
Sensitivity
The results of the sensitivity analysis show that varying the test
cost had the greatest impact on total service costs whilst varying
the proportion of appointments undertaken by genetic counsel-
lors had the least impact on overall cost of service (Table 4).
Discussion
The detailed costing analysis presented here provides an in-
sight into the resources required in the delivery of the current
cancer genetic service for breast and ovarian cancer. The path-
ways address the whole model of referral to cancer genetic
services including referral, stratification and management of
patients; furthermore, this model of delivery is similar to ser-
vices for other cancer genetic conditions such as referrals for
colorectal cancer risk. Twenty-eight patient pathways were
identified with associated costs ranging from £376.51 to
£13,553.10 (difference of £13,176.59) depending on the test-
ing strategy and management plan for the patient.
The burden of cost in the patient pathways presented here lies
in the management of patients, in particular those identified as
carrying a BRCAmutation. To fully evaluate cost-effectiveness,
these data would need to be combined with outcome data, for
example to include the costs saved from cancers prevented
through risk-reducing surgery. The available data suggest that
identifying BRCA mutations is cost-effective (Kwon et al.
2010; Holland et al. 2009; NICE 2013; Griebsch et al. 2006). Of
particular relevance in the UK, the NICE guidance for familial
breast cancer, using economicmodelling, determined that testing
affected or unaffected individuals at a risk threshold of≥5%was
cost-effective inwomenunder 59years (at aCE thresholdof £30,
000), although the clinical guidance recommends testing for
women of any age, at a risk threshold of ≥10% (NICE 2013).
Intuitively, an unaffected individual would be expected to
receive the maximum benefits of genetic testing such as a
reduced incidence of primary cancers. Furthermore, in indi-
viduals found to be mutation negative, cost savings are gen-
erated from reduced surveillance (NICE 2013). From the ser-
vice perspective, the most cost-efficient strategy would be to
identify unaffected relatives from an affected individual in
whom a BRCA mutation has been identified. These pathways
are demonstrated to have an average cost of £3118.45
Table 4 Sensitivity analysis of total service cost in 6-month period
Sensitivity analysis Cost varied Cost of service during audit period (£)
Base case cost (100 % consultant
appointments, 100 % face to face
appointments, cost of test £540,
London weighting)
387,409
Removal of London weighting 377,801
Varying test cost Test at £300 375,169
Test at £400 380,269
Test at £600 390,469
Test at £700 395,569
Test at £1000 410,869
Varying proportion of consultant appointments 25 % consultant, 75 % genetic counsellor appointments 377,594
50 % consultant, 50 % genetic counsellor appointments 380,866
75 % consultant, 25 % genetic counsellor appointments 384,137
Varying proportion of clinic appointments 25 % telephone, 75 % clinic appointments 383,903
50 % telephone, 50 % clinic appointments 380,396
75 % telephone, 25 % clinic appointments 376,890
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(£3299.96 weighted average for the RMH service). Moreover,
these pathways reduce the time and expense of the ‘loops’
seen when an unaffected individual is referred to the cancer
genetic service, but, though eligible, their relative with cancer
has not been offered BRCA testing. In this scenario, i.e. where
BRCA testing is recommended in an affected relative of an
unaffected patient seen in genetics, the average pathway cost
rises to £5376.24 (£4445.15 weighted average for the RMH
service). Two-thirds of patients referred to the cancer genetic
service were unaffected, and only one third of these were from
a family where BRCAmutation testing had been performed in
an affected relative.
One mechanism for reducing the time and expense of these
loops would be if individuals with breast and/or ovarian can-
cer eligible for BRCA testing were more routinely getting
access to genetic testing. Cancer genetic services have restrict-
ed capacity and would be unlikely to be able to deliver testing
comprehensively to cancer patients (Fong et al. 2009).
However, more access to genetic testing could be possible if
testing in cancer patients became integrated into oncology
services. This service model has been termed the
‘mainstreaming’ of genetic testing (Burton 2011; Burton
et al. 2010; Vencken et al. 2013). The MCG programme,
and other initiatives, is implementing mainstreaming for
BRCA testing through oncology (www.mcgprogramme.
com), in close communication with genetics. Although such
initiatives typically lead to higher volumes of tests being
undertaken, the resulting potential cost increases are greatly
mitigated by the adoption of next-generation sequencing,
which is much cheaper than Sanger sequencing.
Furthermore, the identification of more affected individuals
can facilitate efficient cascade testing and preventative mea-
sures potentially saving overall expenditure for the healthcare
provider (NICE 2013).
Additionally, there is potential for this approach to offer
two substantial advantages. Firstly, it would deliver greater
equity of access to BRCA testing at guideline thresholds,
and secondly, it would streamline the clinical pathways mak-
ing them more time-efficient for the patient and the clinical
teams, with the capacity to accommodate growing demand. It
is likely that the integration of cancer genetic testing into rou-
tine patient pathways in oncology, in close liaison with genetic
services, will prove to be the optimal pathway for most cancer
patients. However, cost-effectiveness analysis is required to
better understand the benefits that would be gained both from
implementing new sequencing technologies and from broad-
ening of testing access.
Our paper has provided a basis for understanding what
resources are currently being used in cancer genetic services
so that policy makers can better understand the starting point
for integrating cancer gene testing into cancer care. Along
with the development of mainstream testing pathways, and
the harnessing of new sequencing technologies for clinical
diagnostics, a comprehensive translational evidence base in-
cluding service evaluation, economic evidence and careful
consideration of the resource allocation challenges are essen-
tial to making genomic medicine a reality (Buchanan et al.
2013; Sullivan et al. 2012).
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